Last reviewed · How we verify
clozapine plus fluvoxamine
Clozapine plus fluvoxamine, marketed by Taipei Medical University Hospital, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk is the lack of clear primary indication and revenue data, which may limit strategic planning and market positioning.
At a glance
| Generic name | clozapine plus fluvoxamine |
|---|---|
| Sponsor | Taipei Medical University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- YouScript IMPACT Registry
- Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine (PHASE4)
- Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clozapine plus fluvoxamine CI brief — competitive landscape report
- clozapine plus fluvoxamine updates RSS · CI watch RSS
- Taipei Medical University Hospital portfolio CI